Healthcare - Biotechnology - NASDAQ - US
$ 8.78
-3.41 %
$ 600 M
Market Cap
-1.53
P/E
CASH FLOW STATEMENT
-138 M
OPERATING CASH FLOW
-1.63 M
INVESTING CASH FLOW
368 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Phathom Pharmaceuticals, Inc.
| Net Income | -202 M |
| Depreciation & Amortization | 575 K |
| Capital Expenditures | -1.63 M |
| Stock-Based Compensation | 45 M |
| Change in Working Capital | -13.6 M |
| Others | 23.1 M |
| Free Cash Flow | -139 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (201.6) | (197.7) | (143.9) | (129.1) | (255.1) | (1.3) |
| Depreciation & Amortization | 0.6 | 0.6 | 0.5 | 0.3 | 8 K | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 95 K | 96.3 | 0 |
| Stock Based Compensation | 45.0 | 24.1 | 16.8 | 5.8 | 0.4 | 0 |
| Other Operating Activities | 32.1 | 21.0 | 5.4 | 1.6 | 131.5 | 50 K |
| Change in Working Capital | (13.6) | 5.4 | (27.5) | 51.7 | (9.5) | 0.2 |
| Cash From Operations | (137.6) | (146.5) | (148.6) | (69.7) | (36.5) | (1.0) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (1.6) | (1.0) | (0.3) | (1.0) | (25.2) | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (1.6) | (1.0) | (0.3) | (1.0) | (25.2) | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 39.3 | 0 | 42.8 | 25.0 | 24.9 | 1.9 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 172.8 | 95.4 | 1.9 | 0.6 | 279.8 | 2 K |
| Cash From Financing Activities | 367.6 | 120.0 | 44.7 | 114.5 | 304.6 | 1.9 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 228.4 | (27.5) | (104.2) | 43.7 | 242.9 | 0.9 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (139.2) | (147.6) | (148.9) | (70.7) | (61.8) | (1.0) |